MetLife Investment Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-63,711
| Closed | -$4.6M | – | 2830 |
|
|
2025
Q4 | $4.6M | Buy |
63,711
+4,433
| +7% | +$286K | 0.02% | 668 |
|
|
2025
Q3 | $2.58M | Sell |
59,278
-8,873
| -13% | -$359K | 0.01% | 966 |
|
|
2025
Q2 | $1.94M | Buy |
68,151
+2,278
| +3% | +$67.9K | 0.01% | 1009 |
|
|
2025
Q1 | $1.94M | Sell |
65,873
-922
| -1% | -$28.7K | 0.01% | 1049 |
|
|
2024
Q4 | $1.94M | Buy |
66,795
+4,431
| +7% | +$185K | 0.01% | 1062 |
|
|
2024
Q3 | $2.86M | Buy |
62,364
+4,017
| +7% | +$174K | 0.02% | 826 |
|
|
2024
Q2 | $2.38M | Buy |
58,347
+21,014
| +56% | +$603K | 0.01% | 888 |
|
|
2024
Q1 | $953K | Hold |
37,333
| – | – | 0.01% | 1325 |
|
|
2023
Q4 | $338K | Hold |
37,333
| – | – | ﹤0.01% | 1920 |
|
|
2023
Q3 | $238K | Hold |
37,333
| – | – | ﹤0.01% | 2104 |
|
|
2023
Q2 | $414K | Buy |
37,333
+3,015
| +9% | +$37.8K | ﹤0.01% | 1828 |
|
|
2023
Q1 | $527K | Buy |
34,318
+6,241
| +22% | +$137K | ﹤0.01% | 1608 |
|
|
2022
Q4 | $623K | Buy |
28,077
+2,469
| +10% | +$36.8K | ﹤0.01% | 1499 |
|
|
2022
Q3 | $418K | Hold |
25,608
| – | – | ﹤0.01% | 1762 |
|
|
2022
Q2 | $372K | Buy |
25,608
+6,204
| +32% | +$92.3K | ﹤0.01% | 1867 |
|
|
2022
Q1 | $358K | Buy |
19,404
+7,161
| +58% | +$122K | ﹤0.01% | 1987 |
|
|
2021
Q4 | $291K | Hold |
12,243
| – | – | ﹤0.01% | 1827 |
|
|
2021
Q3 | $302K | Hold |
12,243
| – | – | ﹤0.01% | 1820 |
|
|
2021
Q2 | $303K | Hold |
12,243
| – | – | ﹤0.01% | 1882 |
|
|
2021
Q1 | $267K | Buy |
12,243
+4,847
| +66% | +$119K | ﹤0.01% | 1884 |
|
|
2020
Q4 | $189K | Hold |
7,396
| – | – | ﹤0.01% | 2015 |
|
|
2020
Q3 | $208K | Buy |
+7,396
| New | +$214K | ﹤0.01% | 1845 |
|
Other funds holding RNAM
MetLife Investment Management's RNAM Position: Q1 2026 in Review
MetLife Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 63,711 shares — an estimated $4.6M sold.
MetLife Investment Management first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $4.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- MetLife Investment Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- MetLife Investment Management sold 63,711 Avidity Biosciences shares in Q1 2026, an estimated $4.6M.
- MetLife Investment Management first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- MetLife Investment Management's Avidity Biosciences position peaked at $4.6M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.